Our results support the involvement of SERCA in the etiopathology of LGMDR1 and lay the foundation to explore SERCA2 as well as UPS as novel molecular targets for the treatment of LGMDR1 muscular dystrophy. Here, ATP2A2 is linked to muscular dystrophy.